New Technology– category –
-
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Navigating the Intricacies of Bispecific Antibody Design: Stability and Manufacturability Challenges Explored
Unknown (attributed to Prassanna Rao and Fränze Vorreiter) USA Overview Prassanna Rao and Fränze Vorreiter detail the design strategies and challenges of bispecific antibodies (BsAbs), which bind two distinct antigens simultaneously. BsA... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
Penn Engineering Develops LNP-Based ‘One-Two Punch’ to Transform Oral Cancer Treatment: Co-Delivering p53 & Ciclopirox Significantly Reduces Tumor Burden in Resistant Models
Penn Engineering (University of Pennsylvania) USA Overview Researchers at Penn have developed a lipid nanoparticle (LNP) formulation to co-deliver two drugs, p53 and ciclopirox, for oral cancer treatment. This LNP platform aims to simult... -
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approval of First PROTAC Vepdegestrant Raises New Challenges in Targeted Protein Degradation Patent Strategy
Elkington and Fife UK Overview The FDA approval of vepdegestrant, the first PROTAC, marks a significant milestone for targeted protein degradation (TPD), bringing complex intellectual property considerations to the forefront. The unique ... -
GLP-1 Receptor Agonist Research Rapidly Expanding Across MASLD–MASH–HCC Continuum: US Leads, China Shows Rapid Growth
Frontiers Switzerland Overview Research on GLP-1 Receptor Agonists (GLP-1RAs) in the context of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MASH (Metabolic Dysfunction-Associated Steatohepatitis), and HCC (Hepatocel... -
Oral GLP-1 Drugs May Quash Brain’s Food Craving Circuit, NIH-Funded Study Suggests Role in Hedonic Eating and Addiction
ScienceDaily USA Overview A study funded by the NIH suggests that newer oral small-molecule GLP-1 drugs, such as orforglipron and danuglipron, may reduce hedonic feeding (eating for pleasure) by affecting a reward circuit in the brain. T... -
Allogene Therapeutics’ Off-the-Shelf CAR T Cema-Cel Receives FDA RMAT & Fast Track Designations for First-Line MRD-Positive LBCL, Achieves 58.3% MRD-Negativity in Phase 2 Interim Analysis
Allogene Therapeutics Press Release USA Overview Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel), an off-the-shelf anti-CD19 CAR T-cell therapy, received both Regenerative Medicine Advanced Therapy (RMAT) and ... -
Henlius Initiates First-in-Human Dosing for STEAP1×CD3×CD28 Trispecific TCE HLX3902 in Metastatic Castration-Resistant Prostate Cancer and Advanced Solid Tumors
Henlius Biotech Press Release China Overview Shanghai Henlius Biotech announced the first patient dosing in a first-in-human (FIH) study for HLX3902, a trispecific T-cell engager (TCE) targeting STEAP1×CD3×CD28. This innovative trispecif...
